@article{TCR9286,
author = {Kentaro Minagawa and Antonio Di Stasi},
title = {Novel toxicology challenges in the era of chimeric antigen receptor T-cells therapies},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 3},
year = {2016},
keywords = {},
abstract = {T-lymphocytes are fine executioners of adaptive immune-responses, however, quantitative and qualitative immunological defects in patients with cancer (1), together with tumor immune-evasion strategies can result in inefficient anti-tumor surveillance (2). Genetically engineered T-cells, redirected towards the CD19 antigen with chimeric antigen receptors (CARs), have proven successful in treating patients with relapsed/refractory acute lymphoblastic leukemia (ALL). In addition, CAR T-cells redirected towards tumor associated antigens are actively being investigated in a variety of malignancies, including solid cancers (3).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/9286}
}